October 30, 2014 | Kamada has been awarded orphan drug status from the US Food & Drug Administration for Glassia, a drug to treat Graft-versus-host-disease (GVHD). When a company receives orphan drug status they are able to receive grant money, tax credits and seven years of marketing exclusivity, with the possibility for an extended regulatory process. Preliminary human and animals studies show that Glassia may be able to treat and reduce the severity of of GVHD, one of the key complications that occurs in stem cell transplantation. Kamida is a biopharmaceutical company based in Israel co-founded by CEO David Tsur.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Non-Profit Launches 10M Shekel Fund For Israeli Small Businesses
December 06, 2023

Amid War, Program Helps Open US Doors For 10 Israeli Startups
December 06, 2023

Israeli Data Privacy Startup Raises $30M in Wartime
December 05, 2023

Israel Awards ‘World’s First’ License For Drone Flights
December 05, 2023
Facebook comments